Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study.


Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
07 Aug 2024
Historique:
received: 08 05 2024
accepted: 24 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 7 8 2024
Statut: epublish

Résumé

Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal treatment, without adequate mycological evidence. Over the past years, wide use of antifungal prophylaxis resulted in decreased occurrence of IFD but has contributed to changes in the spectrum of fungal pathogens, revealing the occurrence of previously rare fungal genera causing breakthrough infections. The expanding spectrum of clinically relevant fungal pathogens required the implementation of screening approaches permitting broad rather than targeted fungus detection to support timely onset of pre-emptive antifungal treatment. To address this diagnostically important aspect in a prospective setting, we analyzed 935 serial peripheral blood (PB) samples from 195 pediatric and adult patients at high risk for IFD, involving individuals displaying febrile neutropenia during treatment of hematological malignancies or following allogeneic hematopoietic stem cell transplantation. Two different panfungal-PCR-screening methods combined with ensuing fungal genus identification by Sanger sequencing were employed. In the great majority of PB-specimens displaying fungal DNAemia, the findings were transient and revealed fungi commonly regarded as non-pathogenic or rarely pathogenic even in the highly immunocompromised patient setting. Hence, to adequately exploit the diagnostic potential of panfungal-PCR approaches for detecting IFD, particularly if caused by hitherto rarely observed fungal pathogens, it is necessary to confirm the findings by repeated testing and to identify the fungal genus present by ensuing analysis. If applied appropriately, panfungal-PCR-screening can help prevent unnecessary empirical therapy, and conversely, contribute to timely employment of effective pre-emptive antifungal treatment strategies.

Identifiants

pubmed: 39113112
doi: 10.1186/s13045-024-01583-0
pii: 10.1186/s13045-024-01583-0
doi:

Substances chimiques

DNA, Fungal 0
Antifungal Agents 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

63

Subventions

Organisme : 7th Framework Programme (FP7) of the EU (Project FUNGITECT)
ID : 602125
Organisme : 7th Framework Programme (FP7) of the EU (Project FUNGITECT)
ID : 602125

Informations de copyright

© 2024. The Author(s).

Références

Salmanton-Garcia J, Hoenigl M, Gangneux JP, et al. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. Lancet Microbe. 2023;4(1):e47–56.
doi: 10.1016/S2666-5247(22)00261-0 pubmed: 36463916
Landlinger C, Baskova L, Preuner S, Willinger B, Buchta V, Lion T. Identification of fungal species by fragment length analysis of the internally transcribed spacer 2 region. Eur J Clin Microbiol Infect Dis. 2009;28(6):613–22.
doi: 10.1007/s10096-008-0683-3 pubmed: 19104852
Landlinger C, Preuner S, Baskova L, et al. Diagnosis of invasive fungal infections by a real-time panfungal-PCR assay in immunocompromised pediatric patients. Leukemia. 2010;24(12):2032–8.
doi: 10.1038/leu.2010.209 pubmed: 20882044
Czurda S, Lion T. Prerequisites for control of Contamination in Fungal diagnosis. Methods Mol Biol. 2017;1508:249–55.
doi: 10.1007/978-1-4939-6515-1_13 pubmed: 27837508
Denham ST, Wambaugh MA, Brown JCS. How environmental Fungi cause a range of clinical outcomes in susceptible hosts. J Mol Biol. 2019;431(16):2982–3009.
doi: 10.1016/j.jmb.2019.05.003 pubmed: 31078554 pmcid: 6646061
Hoenigl M, Salmanton-Garcia J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21(8):e246–57.
doi: 10.1016/S1473-3099(20)30784-2 pubmed: 33606997

Auteurs

Chantal Lucini (C)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Klára Obrová (K)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Isabella Krickl (I)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Filomena Nogueira (F)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Iva Kocmanová (I)

Department of Clinical Microbiology and Immunology, University Hospital Brno, Brno, Czech Republic.

Susanne Herndlhofer (S)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

Karoline V Gleixner (KV)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Wolfgang R Sperr (WR)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Tijana Frank (T)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Nuno Andrade (N)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.

Christina Peters (C)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.
Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Gernot Engstler (G)

Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Michael Dworzak (M)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.
Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Andishe Attarbaschi (A)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.
Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Martine van Grotel (M)

Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands.

Marry M van den Heuvel-Eibrink (MM)

Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands.
Division of Childhealth, Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, the Netherlands.

Ivan S Moiseev (IS)

RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation.

Yuliya Rogacheva (Y)

RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation.

Ludmilla Zubarovskaya (L)

RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation.

Natalia Zubarovskaya (N)

Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Herbert Pichler (H)

Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Anita Lawitschka (A)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.
Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Elisabeth Koller (E)

3rd Medical Dept, Hanusch Hospital, Vienna, Austria.

Felix Keil (F)

Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
3rd Medical Dept, Hanusch Hospital, Vienna, Austria.

Jiří Mayer (J)

Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Department of Internal Medicine-Haematology and Oncology, Masaryk University, Brno, Czech Republic.

Barbora Weinbergerová (B)

Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Department of Internal Medicine-Haematology and Oncology, Masaryk University, Brno, Czech Republic.

Peter Valent (P)

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Thomas Lion (T)

St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria. thomas.lion@ccri.at.
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. thomas.lion@ccri.at.
Department of Paediatrics, Medical University of Vienna, Vienna, Austria. thomas.lion@ccri.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH